YD Biopharma looks to publicly list itself through SPAC deal with Breeze Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2024
0mins
Source: SeekingAlpha
Merger Announcement: Breeze Holdings Acquisition has entered a definitive agreement to merge with YD Biopharma, aiming for a listing on the Nasdaq Capital Market through a SPAC deal.
Enterprise Value Details: The combined company will have an estimated post-deal enterprise value of $694 million, comprising an equity value of $715 million, $21 million in cash, and no debt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
